Defining cell and gene therapy financial disruption

FoCUS studied the distinguishing components of new durable therapies in clinical development and created the Pipeline Analysis Model. Customize this model for your organization.

Top links

CGTs vs chronic therapies

Financial challenges of CGT

Product profile challenges of CGT

Cell and gene therapy products and pipeline

Approved cell and gene therapy products

CGT pipeline deep dive

Customizing the pipeline numbers

Financing tools and policy considerations for cell and gene therapy

Access to cell and gene therapies can be improved with a financial strategy. Check out the Precision Financing Solutions identified by FoCUS when developing your strategy. Learn potential policy concerns associated with financial solutions.

Top links

Precision Financing Solutions

Selecting Precision Financing Solutions

Policy considerations for financing CGT

Delivering access to cell and gene therapies

Delivering innovative therapies and using new payment models change how care is delivered. Prepare yourself or your organization for these changes

Top links

Access issues for CGTs

Working around the issues

Understanding all stakeholder perspectives

Patients, payers, and developers are on a shared journey to access cell and gene therapies and maintain financial stability. Understand your fellow stakeholders’ perspectives as you address issues from your point of view.

Top links

Patient views and challenges

Payer views and challenges

Developer views and challenges

Perspectives on the use of Precision Financing Solutions

FEATURED RESEARCH

How can self-insured employers prepare for the portfolio impact of high-cost gene therapies coming to market?